Business Daily Media

Men's Weekly

.

Novotech at DIA Announces Expanded Asia Partnerships on Target to Reach 1.4 Billion Patients

  • Written by ACN Newswire
BOSTON, June 27, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech announced today at DIA Global Annual Meeting (24-28 June, Boston Convention and Exhibition Center) that it has signed Memorandums of Understanding (MOUs) with five of the leading medical institutions in the region. The MOU partnership program is designed to give Novotech clients access to an additionl 1.4 billion patients, and specialist investigators with advanced clinical research sites.

Novotech made the announcement at the DIA conference (Booth 1904). https://novotech-cro.com/welcome[1]

Novotech Director of Business Development Barry Murphy who is attending the conference said: "Novotech has now signed five MOUs with medical institutions across the region with two more being signed in Thailand and the Philippines next month.

"Asia is the highest growth region for clinical research in the world, and as the Asia-Pacific CRO, we bring access to the key sites and KOLs to our clients via well-developed partnerships and relationships on the ground in Asia. Our MOUs further formalise these relationships.

"Some of the new MOUs are with the largest institutes in the region, such as the China Medical University Hospital in Taiwan which has more than a 2,000-bed facilities with dedicated clinical trials centres."

The partnerships are designed to give Novotech clients:- Faster start-up times- Access to significant patient database- World-class clinical research - regulatory compliance with FDA, PMDA and EMEA- Outstanding recruiters across many therapeutic areas: breast cancer, lung cancer, colorectal cancer, Hepatitis, SLE, RA, Stroke, Diabetes, etc. - Leading principal investigators

The partnerships involve the provision of professional and medical clinical trial advice to the Novotech team including feasibility, principal investigator selection, and assistance with patient recruitment, while Novotech will promote the clinical research capabilities of these institutions internationally.

Novotech Executive Director, Asia Operations Dr. Yooni Kim said: "The partnerships mean Novotech has dedicated clinical experts within these leading hospital organisations to support and prioritise rapid clinical processes for Novotech biopharma clients.

"Novotech is the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region. We have offices and teams on the ground as well as MOUs and long-term relationships with major hospitals that directly benefit our clients.

"Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets," Dr. Kim said.

Novotech is the Asia-Pacific specialist contract research organization (CRO) established in 1996, headquartered in Australia with offices in 11 countries across the region.

See the latest data on Asia clinical trials here: http://www.novotech-cro.com/resources[2].

About Novotech - www.novotech-cro.com[3] Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

For RFP enquiries: see https://novotech-cro.com/welcome[4]

Novotech DIA ContactDirector of Business DevelopmentBarry Murphy[email protected][5] USA: +1-415-527-8320

Media ContactSusan Fitzpatrick-Napier [email protected]AU: +61 2 8218 2144 USA: +1 415 951 3228ASIA: +65 3159 3427 [6]

Topic: Press release summarySectors: HealthCare[7] http://www.acnnewswire.com From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

References

  1. ^ https://novotech-cro.com/welcome (novotech-cro.com)
  2. ^ http://www.novotech-cro.com/resources (www.novotech-cro.com)
  3. ^ www.novotech-cro.com (www.novotech-cro.com)
  4. ^ https://novotech-cro.com/welcome (novotech-cro.com)
  5. ^ [email protected] (www.acnnewswire.com)
  6. ^ [email protected] (www.acnnewswire.com)
  7. ^ HealthCare (www.acnnewswire.com)

Read more http://www.acnnewswire.com/press-release/english/44322/

Work-life Balance Key to Solving Construction Talent Shortage

New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...

How to Apply for More Jobs in Less Time Using AI Automation

Most job seekers spend 11 to 14 hours per week on applications and still hear nothing back. That's not a motivation problem. That's a process proble...

Why Middle Australia Is Quietly Driving the Shift Away From Car Ownership

The narrative around changing attitudes to car ownership has long focused on Gen Z. Younger Australians are often portrayed as the generation movi...

Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion

Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...